Compare · IDXX vs IMDX
IDXX vs IMDX
Side-by-side comparison of IDEXX Laboratories Inc. (IDXX) and Insight Molecular Diagnostics Inc. (IMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXX and IMDX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $41.68B, about 456.5x IMDX ($91.3M).
- Over the past year, IDXX is down 11.7% and IMDX is down 36.4% - IDXX leads by 24.7 points.
- IDXX has been more active in the news (4 items in the past 4 weeks vs 3 for IMDX).
- IDXX has more recent analyst coverage (25 ratings vs 0 for IMDX).
- Company
- IDEXX Laboratories Inc.
- Insight Molecular Diagnostics Inc.
- Price
- $562.28+2.76%
- $2.92-4.89%
- Market cap
- $41.68B
- $91.3M
- 1M return
- +11.02%
- -26.20%
- 1Y return
- -11.70%
- -36.35%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 0
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest IDXX
- Goldman initiated coverage on IDEXX Labs with a new price target
- KeyBanc Capital Markets initiated coverage on IDEXX Labs
- IDEXX Laboratories to Release 2026 Third Quarter Financial Results
- Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
- IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
- IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
- Director Kingsley Lawrence D exercised 2,203 shares at a strike of $114.17 and sold $1,172,178 worth of shares (2,203 units at $532.08) (SEC Form 4)
- IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
- EVP, CFO and Treasurer Emerson Andrew exercised 265 shares at a strike of $178.26 and covered exercise/tax liability with 86 shares, increasing direct ownership by 4% to 4,421 units (SEC Form 4)
- IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
Latest IMDX
- iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch
- iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
- Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
- SEC Form 10-Q filed by Insight Molecular Diagnostics Inc.
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
- SEC Form S-8 filed by Insight Molecular Diagnostics Inc.